PMID- 32754040
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Berberine Ameliorates Subarachnoid Hemorrhage Injury via Induction of Sirtuin 1 
      and Inhibiting HMGB1/Nf-kappaB Pathway.
PG  - 1073
LID - 10.3389/fphar.2020.01073 [doi]
LID - 1073
AB  - Excessive cerebral inflammation plays a key role in early brain injury (EBI) 
      after subarachnoid hemorrhage (SAH). Berberine, an isoquinoline alkaloid isolated 
      from Chinese herb Coptis chinensis, possesses anti-inflammatory, and 
      neuroprotective effects. Here we evaluated the beneficial effects of berberine 
      against SAH-induced inflammatory response and the subsequent brain injury. Our 
      data showed that berberine treatment significantly inhibited microglia activation 
      and proinflammatory cytokines release. Concomitant with suppressed cerebral 
      inflammation, berberine mitigated the subsequent brain injury as demonstrated by 
      improved neurological behavior, reduced brain edema, and decreased neural 
      apoptosis. Moreover, berberine significantly inhibited high mobile group box 1 
      (HMGB1)/nuclear factor-kappaB (Nf-kappaB)-dependent pathway and enhanced sirtuin 1 
      (SIRT1) expression after SAH. Treatment with ex527, a selective SIRT1 inhibitor, 
      reversed berberine-induced SIRT1 activation and inhibitory effects on HMGB1/Nf-kappaB 
      activation. In addition, ex527 pretreatment abated the anti-inflammatory and 
      neuroprotective effects of berberine on SAH. Taken together, these findings 
      suggest that berberine provides beneficial effects against SAH-triggered cerebral 
      inflammation by inhibiting HMGB1/Nf-kappaB pathway, which may be modulated by SIRT1 
      activation.
CI  - Copyright (c) 2020 Zhang, Peng, Zhang, Dong, Wang, Liu, Xia and Zhang.
FAU - Zhang, Xiang-Hua
AU  - Zhang XH
AD  - Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Peng, Lei
AU  - Peng L
AD  - Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Dong, Yi-Peng
AU  - Dong YP
AD  - Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Wang, Cheng-Jun
AU  - Wang CJ
AD  - Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Liu, Cang
AU  - Liu C
AD  - Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Xia, Da-Yong
AU  - Xia DY
AD  - Department of Neurosurgery, The First Affiliated Hospital of Wannan Medical 
      College (Yijishan Hospital of Wannan Medical College), Wuhu, China.
FAU - Zhang, Xiang-Sheng
AU  - Zhang XS
AD  - Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7366844
OTO - NOTNLM
OT  - HMGB1
OT  - Sirtuin 1
OT  - berberine
OT  - inflammation
OT  - subarachnoid hemorrhage
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
PMCR- 2020/07/10
CRDT- 2020/08/06 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
PHST- 2020/07/10 00:00 [pmc-release]
AID - 10.3389/fphar.2020.01073 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Jul 10;11:1073. doi: 10.3389/fphar.2020.01073. eCollection 
      2020.